ReviewFrontiers in physiology2021
Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets.
Review in Frontiers in physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07284446 (Prevalence of Depressive Symptoms and Cognitive Impairment and Their Association With Worse Outcomes in a Cohort of Hospitalized Patients With Chronic Heart Failure), which is not on this map. Cited by 93 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence of Depressive Symptoms and Cognitive Impairment and Their Association With Worse Outcomes in a Cohort of Hospitalized Patients With Chronic Heart Failure
Who cites it
93 citing papers in PubMed, 4 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- Association between constipation and risk of cardiovascular or all-cause mortality: a meta-analysis.Annals of medicine · 2025Pooled it
- The efficacy of transcutaneous vagus nerve stimulation in heart failure management - a systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- Does omega-3 supplementation improve the inflammatory profile of patients with heart failure? a systematic review and meta-analysis.Heart failure reviews · 2023Pooled it
- The impact of platelet-to-lymphocyte ratio on clinical outcomes in heart failure: a systematic review and meta-analysis.Therapeutic advances in cardiovascular diseasePooled it
- Results from the SCIENCE and Danish ASC trials using allogeneic mesenchymal stromal cells to treat ischemic heart failure patients.Regenerative medicine · 2025Trial
- Qiliqiangxin Alleviates Imbalance of Inflammatory Cytokines in Patients with Dilated Cardiomyopathy: A Randomized Controlled Trial.Current medical science · 2024Trial
- Noninvasive low-level tragus stimulation attenuates inflammation and oxidative stress in acute heart failure.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2023Trial
- [A nomogram based on systemic inflammation markers can predict adverse outcomes in patients with heart failure].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Trial
- Prognostic value of 9 immune-inflammatory markers for patients with dilated cardiomyopathy: A retrospective study.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Biological age acceleration predicts mortality and heart failure after acute myocardial infarction in older adults.Journal of geriatric cardiology : JGC · 2026Article
- Article
- Amino Acid-Derived Metabolic Signature Across Stages of Systolic Dysfunction: Derivation and Internal Evaluation of the HASI (Heart Failure Amino Acid-Derived Systolic Index)-40 Index.International journal of molecular sciences · 2026Article
- Characteristics associated with left ventricular diastolic dysfunction and its prognostic implication in patients with sepsis: a prospective cohort study.Journal of anesthesia · 2026Article
- NT-proBNP and hs-CRP may be useful biomarkers for identifying and stratifying repaired TOF patients at increased risk of RV systolic dysfunction.Journal of family medicine and primary care · 2026Article
- Adipose tissue-derived mesenchymal stromal cell therapy in nonischemic heart failure with reduced ejection fraction - ARIISE study design.Future cardiology · 2026Article
- White blood cells and neutrophil-to-high density lipoprotein ratio as predictive markers of left ventricular dysfunction in heart failure.World journal of methodology · 2026Article
- Exploring the Pleiotropic Cardioprotective Effects of GLP-1 Receptor Agonists in Preventing Anthracycline-Induced Cardiotoxicity: A Theoretical Proposal for Future Research.Medicines (Basel, Switzerland) · 2026Review
- Inflammatory Biomarkers and Clinical Outcomes in Hospitalized Patients with COVID-19 and Pre-Existing Heart Failure: A Single-Center Cohort Study.Journal of clinical medicine · 2026Article
- Investigating the inflammatory response to exposure of ultrafine TiOBiochemistry and biophysics reports · 2026Article
- The effect of NSAID use on emergency department visits with decompensated heart failure.International journal of emergency medicine · 2026Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation has been recognized as a major pathophysiological contributor to the entire spectrum of human heart failure (HF), including HF with reduced ejection fraction, HF with preserved ejection fraction, acute HF and cardiogenic shock. Nevertheless, the results of several trials attempting anti-inflammatory strategies in HF patients have not been consistent or motivating and the clinical implementation of anti-inflammatory treatments for HF still requires larger and longer trials, as well as novel and/or more specific drugs. The present work reviews the different inflammatory mechanisms contributing to each type of HF, the major inflammatory mediators involved, namely tumor necrosis factor alpha, the interleukins 1, 6, 8, 10, 18, and 33, C-reactive protein and the enzymes myeloperoxidase and inducible nitric oxide synthase, and their effects on heart function. Furthermore, several trials targeting these mediators or involving other anti-inflammatory treatments in human HF are also described and analyzed. Future therapeutic advances will likely involve tailored anti-inflammatory treatments according to the patient's inflammatory profile, as well as the development of resolution pharmacology aimed at stimulating resolution of inflammation pathways in HF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.